Condition

Clinical trials for Obesity

Active public studies that list Obesity as a condition.

1,102active studies

581recruiting now

69countries represented

838largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowNot applicable

Inflammation, Diabetes, Ethnicity and Obesity Cohort

Obesity, Diabetes MellitusCondition

Intervention not listedTreatment

United States1 locations

University of California, San FranciscoSponsor

Updated 2026-09-08 · NCT03022682See eligibility →

Recruiting nowNot applicable

tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity

ObesityCondition

Sham Transcranial Direct Current Stimulation (tDCS), Active Transcranial Direct Current Stimulation (tDCS)Treatment

United States1 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-09-08 · NCT05225233See eligibility →

Recruiting nowPhase 1

Graded Insulin Suppression Test P&F

Insulin Resistance, HyperinsulinemiaCondition

Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia)Treatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-08 · NCT06592261See eligibility →

Recruiting nowNot applicable

Impact of Overweight, Obesity, and Lifestyle Changes on Work Performance and Well-Being in Medical Residents

Obesity, OverweightCondition

Obesity and Overweight Status, No Intervention (Observational Assessment)Treatment

Italy1 locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSponsor

Updated 2026-09-08 · NCT07677800See eligibility →

Recruiting nowPhase 3

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Diabetes Mellitus, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Brazil74 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07533175See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC0721-8060, SemaglutideTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07767175See eligibility →

Recruiting nowNot applicable

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

Overweight, ObesityCondition

Standard Diet, Ketogenic DietTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-04 · NCT06044935See eligibility →

Recruiting nowEarly Phase 1

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

MASLD, ObesityCondition

TirzepatideTreatment

United States1 locations

University of New MexicoSponsor

Updated 2026-09-04 · NCT06934642See eligibility →

Recruiting nowPhase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia783 locations

AmgenSponsor

Updated 2026-09-03 · NCT07037433See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowNot applicable

New Heart Imaging Techniques to Evaluate Possible Heart Disease

Healthy, ObesityCondition

MR Imaging Techniques - 1, MR Imaging Techniques - 2Treatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-03 · NCT01399385See eligibility →

Recruiting nowEarly Phase 1

Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

Hypertension, ObesityCondition

Neuropeptide YTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-03 · NCT04838678See eligibility →

Recruiting nowNot applicable

Ketogenic Diet and Diabetes Demonstration Project

Type 2 Diabetes, PreDiabetesCondition

Ketogenic diet, Low Fat dietTreatment

United States1 locations

University of New MexicoSponsor

Updated 2026-09-03 · NCT06115265See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Overweight, ObesityCondition

RO7795081, PlaceboTreatment

Netherlands1 locations

Hoffmann-La RocheSponsor

Updated 2026-09-03 · NCT06982131See eligibility →

Recruiting nowNot applicable

Interoception and Illness Perception Before and After Bariatric Surgery: Impact on Disordered Eating (Interoceptiv-BAR)

ObesityCondition

Intervention not listedTreatment

Italy1 locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSponsor

Updated 2026-09-03 · NCT07594275See eligibility →

Recruiting nowPhase 1

A Study to Evaluate ALN-6222 in Participants With Obesity

ObesityCondition

ALN-6222, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-09-03 · NCT07624071See eligibility →

Recruiting nowNot applicable

Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists

Obesity, Emotional EatingCondition

Intervention not listedTreatment

Turkey (Türkiye)1 locations

TC Erciyes UniversitySponsor

Updated 2026-09-03 · NCT07803185See eligibility →

Recruiting nowPhase 1

A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo

Overweight, ObesityCondition

NNC0487-0111, PlaceboTreatment

Denmark, Netherlands2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-02 · NCT07757087See eligibility →

Recruiting nowNot applicable

Effects of Obesity in the Aged

Obesity, AgingCondition

Mechanical unloading of the Thorax using an external cuirassTreatment

United States1 locations

University of Texas Southwestern Medical CenterSponsor

Updated 2026-09-02 · NCT05028309See eligibility →

Recruiting nowPhase 2

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Overweight, Overweight and ObesityCondition

Counseling, Text MessagesTreatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-09-02 · NCT05770570See eligibility →

Recruiting nowPhase 1

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors

Healthy Participants, ObesityCondition

Placebo, ACI-19764 at dose A1Treatment

Netherlands1 locations

AC Immune SASponsor

Updated 2026-09-02 · NCT07463196See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, SemaglutideTreatment

Australia, Bulgaria59 locations

KaileraSponsor

Updated 2026-09-01 · NCT07284979See eligibility →

Recruiting nowNot applicable

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Metabolic Disease, ObesityCondition

NSR IDE-MRI: Research pulse sequencesTreatment

United States3 locations

National Heart, Lung, and Blood Institute (NHLBI)Sponsor

Updated 2026-09-01 · NCT01143454See eligibility →

Recruiting nowPhase 1

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4174794, LY4174794Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-01 · NCT07654972See eligibility →

Recruiting nowNot applicable

HealthyTogether: RCT of a Dyadic Weight Management Intervention

Obesity, OverweightCondition

HealthyTogetherTreatment

United States2 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-09-01 · NCT06619041See eligibility →

Recruiting nowNot applicable

Physical and Behavioral Traits of Overweight and Obese Adults

Obesity, Healthy VolunteersCondition

Intervention not listedTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-01 · NCT00428987See eligibility →

Recruiting nowNot applicable

Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention

Cardiovascular Disease, ObesityCondition

Intervention not listedTreatment

United States1 locations

National Heart, Lung, and Blood Institute (NHLBI)Sponsor

Updated 2026-09-01 · NCT01927783See eligibility →

Recruiting nowNot applicable

Children s Growth and Behavior Study

Obesity, Eating BehaviorsCondition

Intervention not listedTreatment

United States1 locations

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Sponsor

Updated 2026-09-01 · NCT02390765See eligibility →

Recruiting nowNot applicable

Investigating the Impact of Obesity on Pubertal Development in Girls

Obesity, PubertyCondition

Intervention not listedTreatment

United States1 locations

National Institute of Environmental Health Sciences (NIEHS)Sponsor

Updated 2026-09-01 · NCT02583646See eligibility →

Recruiting nowNot applicable

Early Tracking of Childhood Health Determinants (ETCHED) Study

Diabetes Mellitus, ObesityCondition

Intervention not listedTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-01 · NCT03481829See eligibility →

Recruiting nowPhase 1, Phase 2

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

Obesity, Metabolic SyndromeCondition

Empagliflozin 25 MG, PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-09-01 · NCT05972564See eligibility →

Recruiting nowPhase 1

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)Condition

NNC6022-0004, PlaceboTreatment

Netherlands1 locations

Novo Nordisk A/SSponsor

Updated 2026-09-01 · NCT07693868See eligibility →

Recruiting nowNot applicable

TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass

Morbid Obesity, ObesityCondition

TSBL-based biliopancreatic limb length determination, BMI-based biliopancreatic limb length determinationTreatment

Kazakhstan1 locations

National Scientific Center of Surgery named after A.N.SyzganovSponsor

Updated 2026-09-01 · NCT07796503See eligibility →

Recruiting nowPhase 3

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Obesity, Type 2 DiabetesCondition

Cagrisema, SemaglutideTreatment

Argentina, Australia303 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07564414See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowNot applicable

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia

Endometrial Carcinoma, ObesityCondition

CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-ReferralTreatment

United States2 locations

Dana-Farber Cancer InstituteSponsor

Updated 2026-08-31 · NCT04839614See eligibility →

Recruiting nowNot applicable

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

ObesityCondition

Step it Up mobile app, Global Positioning System (GPS) DeviceTreatment

United States1 locations

National Heart, Lung, and Blood Institute (NHLBI)Sponsor

Updated 2026-08-31 · NCT03288207See eligibility →

Recruiting nowPhase 4

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Pre-diabetes, ObesityCondition

Mirabegron 50 MG, Tadalafil 10 MGTreatment

United States1 locations

Philip KernSponsor

Updated 2026-08-31 · NCT05051436See eligibility →

Recruiting nowPhase 3

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Knee Osteoarthritis, ObesityCondition

Ecnoglutide Injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07734311See eligibility →

Recruiting nowNot applicable

Diabetes and Heart Disease Risk in Blacks

Cardiovascular Diseases, DiabetesCondition

Intervention not listedTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-08-28 · NCT00001853See eligibility →

Recruiting nowNot applicable

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Obesity, Normal PhysiologyCondition

+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, fastingTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-08-28 · NCT05545306See eligibility →

Recruiting nowPhase 3

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

OSA - Obstructive Sleep Apnea, ObesityCondition

XW003 injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07387094See eligibility →

Recruiting nowPhase 3

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

OSA - Obstructive Sleep Apnea, ObesityCondition

XW003 injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07434050See eligibility →

Recruiting nowPhase 3

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-08-27 · NCT07503210See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 4

GLP-1R Actions on Muscle and the Skeleton

Musculoskeletal Abnormalities, ObesityCondition

Tirzepatide, Lifestyle toolkitTreatment

United States2 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-08-27 · NCT07154719See eligibility →

Recruiting nowNot applicable

PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry

ObesityCondition

Biospecimen collectionTreatment

United States1 locations

CorEvitasSponsor

Updated 2026-08-27 · NCT07598981See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related conditions

Obesity & Overweight220 Overweight205 Overweight and Obesity130 Type 2 Diabetes108 Hypertension107

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.